National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes
Search
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
New analysis supports long-term treatment with Ofev® in SSc-ILD patients
Translating Human Pharma Science into Animal Health Innovation
Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health
Interchangeable Biosimilar Now on Express Scripts® Formulary
Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018
New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)
New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)
Investigational Compound Granted FDA Orphan Drug Designation
U.S. FDA Grants Orphan Drug Designation to Investigational Compound for Idiopathic Pulmonary Fibrosis
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
HBA Rising Star & Luminary Awards | Boehringer Ingelheim US
Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.
FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US
FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.
Six creative Connecticut students turn aspiring ideas into inventive innovation
Learn about the 2023 Connecticut Invention Convention winners.
Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage
Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Our Mission
Our Story
Consumer Health Data Privacy Statement
This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD